Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
berberine + atorvastatin + rosuvastatin
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of berberine (a natural alkaloid) and two statin medications (atorvastatin and rosuvastatin). This combination potentially offers enhanced lipid-lowering effects through complementary mechanisms. Berberine promotes OATP1B1 expression and increases statin uptake by hepatocytes, while the statins inhibit HMG-CoA reductase. The combination may allow for lower statin doses while maintaining or improving efficacy in treating hyperlipidemia and reducing cardiovascular risk.
02
Targets
FXR (Farnesoid x-activated receptor)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)NR1H3 (Liver X receptor beta)ABCB1 (P-glycoprotein)LDLR (Low-density lipoprotein receptor)
Beyond the preview
Go deeper on berberine + atorvastatin + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on berberine + atorvastatin + rosuvastatin.